Incyte: The Worst Has Been Avoided

In my estimation, the acquisition has allowed Incyte to significantly strengthen its portfolio of experimental drugs aimed at combating inflammatory diseases such as chronic spontaneous urticaria, atopic dermatitis, cholestatic pruritus, and more. Source: Escient Pharmaceuticals In addition, Incyte has a rich portfolio of FDA-approved medications, many of which remain the "gold standards" for the treatment of myelofibrosis, vitiligo, and graftversus-host disease (GvHD). So, Opzelura is a cream form of ruxol ...